Figure 1. Therapeutic effect of CBA-PEDF-AAV2 on choroidal neovascularization development and antibody responses to AAV2 capsid following single and sequential intravitreal injections. A-D: Representative CNV images from mouse eyes that were untreated (A), received a single intravitreal (IV) treatment (B), received first IV treatment (C), and received a second IV treatment (D) of AAV2-PEDF. E: The therapeutic effect of CBA-PEDF-AAV2 on CNV development was evaluated in animals that received single IV ocular injections in naïve and preimmunized mice (5 animals each type of injection), and two sequential IV injections (15 animals were used). The CNV area was averaged from 25 laser lesions (from 5 mice) for mice that received a single IV injection and pre-intramuscular (pre-IM) administration of the vector, and 75 laser lesions (from 15 mice) for mice that received two sequential intravitreal injections (2X-IV). F: Antibody response to AAV2 capsid in animals received a single intramuscular injection, intravitreal, and two sequential intravitreal injections overtime. Five animals for each type vector injection were used. Arrow indicates the second injection time.